You may not log in without verifying your email address.
Please check your email (including your spam email) for the Welcome message that was sent.
PDK1/Akt/Flt Dual Pathway Inhibitor is a cell-permeable compound that selectively induces apoptosis in AML (Acute Myelogenous Leukemia) with little effect on normal CD34+ AML progenitor cells. Directly inhibit both PDK1 and Akt activities in in vitro kinase assays in a dose-dependent manner and block cellular phosphorylation of Akt at both Ser473 and Thr308. PDK1/Akt/Flt Dual Pathway Inhibitor's dual inhibition nature against both PDK1/Akt and Flt3/PIM signaling pathways allows effective elimination of AML cells that are otherwise resistant to inhibitors that target only the PDK1/Akt pathway.
Zeng, Z., et al. 2006. Cancer Res. 66, 3737. Koul, D., et al. 2006. Mol. Cancer Ther. 5, 637. Mandal. M., et al. 2006. Oral Oncol. 42, 430. Mandal. M., et al. 2005. Br. J. Cancer 92, 1899.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.